Ubs Asset Management Americas Inc Intellia Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 637,861 shares of NTLA stock, worth $13.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
637,861
Previous 521,706
22.26%
Holding current value
$13.1 Million
Previous $3.71 Million
61.31%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding NTLA
# of Institutions
333Shares Held
97.2MCall Options Held
1.66MPut Options Held
1.03M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$267 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$223 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$197 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.12MShares$84.6 Million0.0% of portfolio
-
State Street Corp Boston, MA4.04MShares$83 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.56B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...